2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Neoplasm Metastasis
5
Sarcoma
2
Thyroid Neoplasms
1
Thyroid Diseases
1
Thoracic Neoplasms
1
Solitary Fibrous Tumors
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Follicular
1
Lymphoma
1
Lung Neoplasms
1
Lung Diseases
1
Liver Diseases
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Granuloma, Plasma Cell
1
Glioma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Endocrine System Diseases
1
Interventions
Temozolomide
163
Radiosurgery
128
Radiotherapy
106
Bevacizumab
97
Magnetic Resonance Spectroscopy
74
Carboplatin
48
Surgical Procedures, Operative
35
Etoposide
34
pembrolizumab
33
Radiation
33
Nivolumab
33
Irinotecan
33
Cyclophosphamide
33
Erlotinib Hydrochloride
31
Carmustine
28
Trastuzumab
25
Lomustine
25
Cisplatin
25
Ipilimumab
24
Filgrastim
23
Mental Status and Dementia Tests
21
Magnetic Resonance Imaging
21
Aminolevulinic Acid
21
Vincristine
20
Surveys and Questionnaires
19
Capecitabine
19
Topotecan
18
Specimen Handling
18
Pemetrexed
18
Radiotherapy, Intensity-Modulated
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
repotrectinib
×
Clear all
NCT06315010
2026-02-25
REPOSE
MedSIR
Phase 2
Recruiting
20 enrolled